I. General Introduction

S INCE ITS DISCOVERY in 1973 by
(1), knowledge of the functional role of somatostatin (SS) in regulating neurotransmission in the brain, as well as in the regulation of secretion processes in the anterior pituitary gland, the pancreas, and the gastrointestinal tract, has increased considerably. In addition to playing an important regulatory role in neurotransmission and secretion, the peptide may control cell proliferation in normal and tumorous tissues as well (2, 3) . Between 1992 and 1994, five SS receptor (sst) subtype genes were cloned and characterized; they were code-named sst 1 , sst 2 , sst 3 , sst 4 , and sst 5 (4) . The discovery of these genes initiated a large number of studies directed to elucidate their expression in SS-target tissues, their selectivity of binding of structural SS-analogs, and their coupling to the different second messenger systems known to be activated upon SS binding to its receptor. This has been reviewed extensively (5) (6) (7) (8) (9) . The discovery of the sst subtype genes also initiated the development of a large series of novel SSanalogs that selectively bind to sst subtypes. Currently, a number of these sst subtype-selective analogs are being tested for their in vivo and in vitro potencies to modulate hormone secretion and/or cell proliferation (8, 10) . The high density of SS receptors on human neuroendocrine tumors originating from normal SS target tissues has been used clinically to treat symptoms of hormonal hypersecretion in patients with GH-or TSH-secreting pituitary adenomas, as well as in patients harboring islet cell or carcinoid tumors with SS-analogs (11) . However, although SS-analogs effectively control hormonal hypersecretion by neuroendocrine tumors, their effects are often transient, and considerable differences between patients harboring islet cell and carcinoid tumors exist with respect to the development of tachyphylaxis. In addition, the presence of a high density of SS receptors on human neuroendocrine tumors has allowed the development in 1989 (2, 12) of the technique of sst scintigraphy using radiolabeled SS-analogs to visualize sst-positive tumors in vivo (2, 13) .
The above physiological and pathophysiological roles of SS and the presence of SS receptors on neuroendocrine tumors have been reviewed extensively. Much less attention has been paid to the clinical importance of sst internalization in determining the uptake of radiolabeled SS-analogs by sst-positive neuroendocrine tumors and the role of individual sst subtypes herein, as well as to the mechanisms in-volved in tachyphylaxis to SS-analog therapy. This manuscript gives an overview of the current knowledge on the internalization and cellular uptake of radiolabeled SSanalogs by sst-positive tumor cells and the involvement of endogenously expressed sst subtypes in this process, as well as the clinical consequences of sst internalization for ssttargeted radio-or chemotherapy. Section III of this review addresses the potential mechanisms involved in tachyphylaxis after long-term treatment of patients with neuroendocrine tumors with SS-analogs.
A. SS and sst subtypes
SS is a small cyclic peptide that is widely expressed throughout the central nervous system and peripheral tissues. In peripheral tissues, SS exerts predominantly inhibitory actions (14) on secretion processes, whereas the peptide acts as a neurotransmitter in both a stimulatory and inhibitory manner in the brain (15). SS is formed by proteolytic processing of larger precursor molecules, i.e., prepro-SS and pro-SS. After cleavage of the pro-SS molecule, two biologically active forms of SS consisting of 14 (SS-14) or 28 (SS-28) amino acids are generated (16). SS-14 and SS-28 act via highaffinity G protein-coupled membrane receptors. Five sst subtypes have been cloned and characterized. The genes encoding the five sst subtypes are localized on different chromosomes (8) . Via alternative splicing, two forms of the sst 2 receptor can be generated, i.e., sst 2A and sst 2B (17, 18). The only difference between sst 2A and sst 2B is the length of their cytoplasmic tail. The five sst subtypes share a coupling to the second messenger systems known to be activated upon SS binding to its receptor. These systems include inhibition of adenylyl cyclase activity and activity of calcium channels, as well as stimulation of phosphotyrosine phosphatase or MAPK activity. This has been reviewed extensively (7) (8) (9) . Although the inhibitory effects on adenylate cyclase activity and on the influx of Ca 2ϩ are linked to inhibition of secretion processes, the activation of phosphotyrosine phosphatase or MAPK activity may play a role in the regulatory effects that SS exerts on cell proliferation (2, 3, 10) . The selective induction of apoptosis mediated via activation of sst 3 receptors is of particular interest in this respect. The role of the individual sst subtypes and the mechanism of action of the antiproliferative effects by SS have been reviewed recently (9) . The five sst subtypes all bind SS-14 and SS-28 with high affinity but can be divided into two subclasses on their ability to bind structural octapeptide analogs of SS. The sst 1 and sst 4 receptors do not bind octapeptide SS-analogs, whereas sst 2A , sst 3 , and sst 5 receptors display a high, low, and moderate affinity, respectively, toward octapeptide SS-analogs such as the clinically used octreotide and lanreotide (Table 1) .
B. SS receptor subtype expression in normal and tumorous human tissues
Classical SS-target tissues such as the central nervous system, the anterior pituitary gland, and the pancreas express multiple sst subtypes. The expression of sst subtypes in the brain has only been studied extensively in rodent species. In the brain, mRNAs encoding for all five sst subtypes are expressed in a highly specific pattern (8) . This regional, characteristic expression pattern of sst subtypes in the brain has recently been confirmed at the protein level by immunohistochemical techniques using sst subtype-specific antibodies (19). The adult human pituitary gland expresses sst 1 , sst 2 , sst 3 , and sst 5 mRNAs, but not sst 4 mRNA (20). In addition, human pancreatic islet cells express all five sst subtype proteins, as determined by immunohistochemistry (21, 22) . In human islets, sst 1 , sst 2 , and sst 5 receptors are the most abundantly expressed subtypes, with a high percentage of ␤-cells expressing sst 1 and sst 5 , ␣-cells expressing sst 2 , and ␦-cells expressing sst 5 
(22).
Neuroendocrine tumors, which often originate from SStarget tissues, frequently express a high density of SS receptors (23-26). The sst-expressing human tumors include pituitary adenomas, islet cell tumors, carcinoids, paragangliomas, pheochromocytomas, small cell lung cancers, and medullary thyroid carcinomas (MTCs), but also breast cancers and malignant lymphomas (24, 27). The sst subtype expression in different types of human cancers has been demonstrated at the mRNA level using in situ hybridization (28, 29), RNase protection assays, and RT-PCR (20, 27, 30 -34). The majority of human sst-positive tumors simultaneously express multiple sst subtypes, although there is a considerable variation in sst subtype expression between the different tumor types and among tumors of the same type. Table 2 shows that sst 2 is the most abundantly expressed receptor subtype in the majority of tumors. Recent studies using antibodies raised against synthetic peptide sequences of the sst 1 , sst 2 , sst 3 , and sst 5 receptor confirmed this variation in the expression of sst subtypes in different types of human tumors (Table 2 ; Refs. 35-38). The higher number of tumors expressing particular sst subtype mRNAs, compared with the number of tumors expressing sst subtype proteins, may be related to the higher sensitivity of techniques such as RT-PCR compared with immunohistochemistry. On the other hand, techniques such as RT-PCR might overestimate the real percentage of tumors expressing sst subtypes because blood vessels, immune cells, stromal and contaminating normal cells, which are present in or surround human tumors, may express sst subtypes as well (29, 39 -41). The predominant expression of sst 2 receptors in human tumors forms the basis for the successful clinical application of octapeptide SS-analogs such as octreotide and lanreotide in controlling symptoms related to hormonal hypersecretion in patients with GH-secreting pituitary adenomas, islet cell tu- mors, or carcinoid tumors (2, 11), but also for the possibility to visualize sst-positive tumors using radiolabeled SSanalogs (see Section II). Knowledge of the sst subtype expression patterns in human neuroendocrine tumors may be very important for the development of the concept of ssttargeted radiotherapy or chemotherapy. As will be discussed below, sst subtypes differ in their ability to internalize receptor-bound ligand, which is a crucial step to direct a SSanalog-linked radioisotope or cytotoxic compound to the nucleus of the tumor cell.
C. Agonist-induced internalization of sst subtypes
Since the cloning of the five sst subtypes, the involvement of the individual sst subtypes in the process of receptormediated internalization of SS has been extensively investigated. Although differences have been reported between human and rat sst subtypes with respect to their dynamics of agonist-induced internalization, Section I.C is focused primarily on human sst subtypes and briefly summarizes their reported ability to undergo internalization after exposure to agonists. The mechanisms involved in receptor-mediated internalization of sst subtypes are not the focus of this review, and they have been reviewed elsewhere (8, 9, (42) (43) (44) (45) (46) . In general, the mechanism and route of internalization of sstagonist complexes follow those described for many other G protein-coupled receptors (47-50) and involve aggregation of the hormone receptor complex in specialized areas of the membrane, followed by internalization of the hormonereceptor complex via clathrin-coated, as well as uncoated, pits (47, 51). After internalization and pit formation, fusion of these vesicles with lysosomes occurs, resulting in hormone degradation or receptor recycling to the cell surface ( Fig. 1 ; Refs. 49, 52, and 53).
The sst subtypes differentially internalize SS and SSanalogs (9) . In Chinese hamster ovary (CHO)-K1 cells stably expressing one of the five human sst subtypes, sst 2 , sst 3 , sst 4 , and sst 5 receptors displayed rapid (within minutes) agonistdependent internalization of [ 125 I]LTT SS-28 ligand in a timeand temperature-dependent manner (54). Maximum internalization of the radioligand occurred within 60 min. The sst 3 -and sst 5 -expressing cells displayed the highest degree of internalization (78% and 66%, respectively), followed by sst 4 (29%) and sst 2 (20%). In contrast, the sst 1 subtype displayed only a very low amount (4%) of internalization. Another study using COS-7 cells transfected with the human sst 1 (hsst 1 ) or hsst 2A receptor subtypes (55) recently confirmed the low internalization rate of the sst 1 subtype. These investigators used confocal microscopy to analyze the fate of internalized novel fluorescent SS derivatives (43). In cells transfected with sst 2A receptors, up to 75% of specifically bound fluorescent ligand was recovered inside the cells within 60 min after agonist exposure, where it clustered into small endosome-like particles (55), whereas the capacity of internalization of SS via the sst 5 receptor was intermediate between sst 1 and sst 2A receptors (43). These particles increased in size over time, suggesting that the receptor-ligand complexes followed an endocytotic pathway.
Recent observations by Rocheville et al. (56) demonstrated that internalization of human sst subtypes can be determined by functional homo-and heterodimerization of sst subtypes as well. The hsst 1 receptors displayed no internalization of their selective ligand 125 I-SCH288, consistent with their inability to undergo agonist-induced internalization as a monotransfectant (57) . However, when hsst 1 receptors were cotransfected with a c-tail deletion mutant of hsst 5 , a slight but significant internalization of 125 I-SCH288 at 60 min was observed. Heterodimerization of epitope-tagged sst 2A and sst 3 receptors prevents agonist-induced endocytosis of sst 3 but not sst 2A receptors (58) . Apart from changes in functionality of individual sst subtypes due to receptor dimerization, sst receptors may also form heterodimers with other G protein-coupled receptors, e.g., dopamine and opioid receptors (59, 60) . Again, such heterodimers have properties different from the individual receptors. Therefore, the knowledge that homo-and heterodimerization of sst subtypes, and of sst subtypes with other G protein-coupled receptors, may influence the capacity of individual sst subtypes to undergo agonist-induced endocytosis clearly indicates the need to study internalization of sst subtypes endogenously expressed in sst-positive cells. Such studies will help to clarify the apparent discrepancies in internalization of specific sst subtypes. The above-described ability of sst subtypes to undergo agonist-induced internalization is an important characteristic of these receptors for transporting radiolabeled SS-analogs into the cell, thereby making sst-targeted radiotherapy a feasible approach to treat patients with neuroendocrine tumors expressing a high density of sst. In Section II, the preclinical evidence for internalization of radiolabeled SS-analogs, resulting in accumulation of intracellular radioactivity, by tumor cells endogenously expressing sst subtypes, is reviewed.
II. Consequences of sst Internalization for sstTargeted Radiotherapy or Chemotherapy of sstPositive Tumors
A. Preclinical evidence for internalization of radiolabeled SS-analogs
Human sst-positive tumors show a high uptake of [ 111 In-DTPA 0 ]octreotide at sst scintigraphy (13) . Analysis of the uptake of [ 111 In-DTPA 0 ]octreotide by scintigraphy is preferably performed 24 h after the injection of the radiopharmaceutical (13) . After 24 h, it is unlikely that the radioactivity in the tumors reflects cell membrane-bound ligand, but in fact, more likely, represents internalized radioligand. Internalization of [ 111 In-DTPA 0 ]octreotide in vivo is also evidenced by our observations in rats, in which uptake of radioactivity in sst-positive organs, such as the pituitary gland and the pancreas, after the injection of the radiopharmaceutical, can be prevented by injection of excess unlabeled octreotide up to 10 min post injection, but not 20 min post injection. At that time, all radioactivity present in the sst-positive tissues probably reflects internalized radioligand (61) . Direct evidence for internalization and subsequent subcellular distribution of radioisotopes delivered to the tumor cells using radiolabeled SS-analogs is presented from several ex vivo and in vitro autoradiographic studies. After incubation of human HT-29 colon carcinoma cells with the 3 H-labeled SS-analog TT-232, radioactivity was observed at the cell surface and cytoplasmic membranes, as well as the nucleus (62 (63) . The primary cultures specifically bound and internalized this radiopharmaceutical. About 50% of the internalized radioactivity was released by the cells within 6 h, whereas the remaining radioactivity was trapped within the cells up to 42 h. Electron microscopic autoradiography demonstrated the presence of the internalized 111 In in the cytoplasm and the nucleus. The same processes also apply to the in vivo situation. From seven patients with malignant midgut carcinoid tumors, who received an iv injection of 200 MBq [ 111 In-DTPA 0 ]octreotide 2 d before abdominal surgery, tumor tissue was obtained and analyzed for the subcellular distribution of radioactivity using ultrastructural autoradiography (64) . In all patients, the carcinoid tumor could be visualized by preoperative scintigraphy. By ex vivo autoradiography, silver grains were found at the plasma membrane, in the cytoplasmic areas among secretory granules and vesicular compartments, but also in the perinuclear area. This localization of 111 In in close proximity to the cell nucleus is especially important for this short range Auger electron-emitting radioisotope to exert its cytotoxic effect As discussed in Section I.A (Table 1) , octapeptide SSanalogs such as octreotide bind with high affinity to sst 2 and with lower affinity to sst 3 and sst 5 (74, 75) . Therefore, both the affinity of the radioligand for the receptor and the efficiency of internalization of the radioligand-receptor complex can be important factors in determining the uptake of radioactivity in sst scintigraphy of sst-positive tumors. Moreover, the differential expression of sst subtypes in tumors (Table 2 ), as well as the level of sst subtype expression, may play a role. Until now, data on the differential internalization of SS by sst subtypes were derived from studies using cell lines transfected to overexpress the individual sst subtypes (Section I.C). Data on the internalization of SS ligands by (tumor) cells endogenously expressing sst subtypes are needed to evaluate the real significance of these findings for human sstpositive tumors. Because most human tumors express multiple sst subtypes, the development of novel sst subtypeselective agonists and antagonists will also be of help to unravel this question. Receptor-mediated endocytosis of SSanalogs is especially important when radiotherapy of human sst-positive tumors using radiolabeled SS-analogs is considered. Internalization of radioligand will result in a prolonged cellular retention of radioactivity, thus resulting in a prolonged exposure of the tumor cell to radiation. Human neu- After internalization of the receptor-radioligand complex, an important process is the retention of radioactivity within the tumor cells. For iodinated SS ligands, it seems clear that a significant proportion of radioactivity is rapidly excreted. This may be due in part to the excretion of radioligand degradation products, although recycling of the receptorligand complex may play a role as well. Recycling of SS receptors after being internalized has been demonstrated for sst 2 (80) and sst 3 (44, 81) receptors. Koenig et al. (80) also showed that biologically active SS agonists were excreted after being internalized by sst 2 -expressing CHO cells. Therefore, trapping of radioisotopes into tumor cells may be an additional important mechanism determining the amount of uptake of radioligand that is used for sst scintigraphy and targeted radiotherapy. In this respect, Duncan et al. (82) previously demonstrated that [ 111 In-DTPA 0 ]octreotide is delivered in vivo to pancreatic tumor cell lysosomes and proposed that lysosomes play a critical role in the cellular physiology of radiolabeled SS-analogs. The internalized [ 111 In-DTPA 0 ]octreotide was shown to be metabolized to 111 In-DTPA-d-Phe in vivo (83, 84) . Accumulation of radioactivity in nuclear-lysosomal density gradient fractions was also found in neuroblastoma cells exposed in vitro to the radioligand (85 (87), demonstrated a bellshaped curve, dependent upon the amount of injected peptide. Studies to determine the optimal peptide mass for uptake of radioactivity in human tumors after the injection of radiolabeled SS-analogs are ongoing (87) .
As shown in Table 1 , different octapeptide SS-analogs such as octreotide, lanreotide, and vapreotide (RC-160) interact with the same subclass of sst subtypes (sst 2 , sst 3 , and sst 5 ). Nevertheless, slightly different affinities for the different sst subtypes have been found (Table 1 ). However, in vivo studies in rats (88) and humans (89) 111 In-or 90 Y-labeled DOTAlanreotide, bound with high affinity to hsst 2 -hsst 5 and with low affinity to hsst 1 expressed in COS-7 cells, suggesting that this radiolabeled peptide may also be useful for sst scintigraphy or radiotherapy (90) . Apart from differences in the affinity profiles of unlabeled SS-analogs due to structural differences, radiolabeling of such analogs has major effects on binding affinity for the different human sst subtypes as well (91) . Yttrium labeling of [DOTA-Tyr 3 ]octreotide, DOTA-lanreotide, and DOTA-RC-160 significantly increases binding affinities for sst 3 and sst 5 receptors. Such differences, in combination with the high internalization rates of sst 3 (77) (78) (79) . Therefore, several characteristics of SS-analogs developed for sst scintigraphy and radiotherapy, such as small structural modifications, chelator substitution, or type of radioisotope, considerably affect binding affinity (91) .
Preclinical studies have shown that down-regulation of SS receptors may occur during agonist exposure. On the other hand, agonist-induced up-regulation of sst expression has been demonstrated as well (see Section III.D.1). Agonistinduced regulation of tumoral sst expression may theoretically influence the results of sst scintigraphy and the efficacy of targeted radiotherapy. The few available clinical data on this issue add to the equivocal data regarding up-regulation and/or down-regulation of SS receptors upon exposure to SS or SS-analog treatment. In five patients with metastatic MTC who were studied before and after 3 months of therapy with a high dose of octreotide, tumor/background ratios determined by sst scintigraphy were reduced in 14 of 18 metastases, suggestive of a down-regulation of SS receptors by octreotide therapy (92) . Moreover, reduced orbital uptake of octreoscan was observed in 10 patients with thyroid eye disease after 3 months of treatment with lanreotide or octreotide (93) . On the other hand, in patients with a somatostatinoma, the tumors can be visualized by sst scintigraphy (94, 95) , suggesting that a complete sst down-regulation does not occur in this type of tumor. Finally, Dorr et al. (96) reported decreased uptake of octreoscan in the liver, spleen, and kidney during continuous octreotide therapy, whereas tumor uptake values were increased simultaneously in five patients with metastatic carcinoid disease and decreased in one patient with advanced MTC. In conclusion, homologous down-regulation of sst expression may be (tumor) cell type specific, as was already evident from experimental studies (see Section III.D.1).
In conclusion, it is well established now that radiolabeled SS-analogs, including those that are used for sst scintigraphy and sst-targeted radiotherapy, can be internalized by sstpositive tumor cells. Several mechanisms may determine the amount of uptake of radiolabeled SS-analogs. These include stability of the radioligand, the expression levels of individual sst subtypes, the affinity of the radioligand for the sst (subtype), the efficiency of receptor internalization and recycling that may be different between sst subtypes, the final trapping of the radioisotopes within the tumor cells, as well as the mass of the injected peptide (summarized in Table 3 ).
B. SS receptor-targeted radiotherapy
1. Preclinical evidence. Several preclinical studies have demonstrated tumor growth-inhibitory effects after treatment with radiolabeled SS-analogs. In athymic mice bearing sstpositive PC-3 prostatic adenocarcinoma, Zamora et al. (97) showed that intratumoral injections with seven 200-Ci doses of the ␤-emitting 188 Re-RC-160 SS-analog reduced tumor size by 90%. Additionally, a significantly higher proportion of survivors was observed in the group treated with 188 Re-RC-160. In this study, treatments were initiated 19 d after inoculation of PC-3 tumor cells when the animals carried solid tumors (500 -1000 mm 3 ). In addition, three serial treatments with regionally injected 200 Ci 188 Re-RC-160 decreased tumor burdens in experimental models of H-69 human small cell lung cancer cells or ZR-75-1 mammary adenocarcinoma cells xenografted into the pleural cavity of athymic mice (98) . Tumor ablation was observed in up to 60% of the animals bearing H69 tumors and in 40% of the animals bearing ZR-75-1 tumors (98) . In another study in nude mice bearing solid sst-positive AR42J pancreatic tumors, a single treatment with 500 Ci of another SSanalog, radiolabeled with the ␤-emitting isotope 90 octreotide. These investigators demonstrated a significant reduction in the number of liver metastases by this treatment regimen in the sst-positive tumor model, but not in the sst-negative tumors. This suggests that the presence of sst on the tumor cells is required for effectiveness of treatment with radiolabeled SS-analogs. This was further confirmed by their observation that the radiotherapeutic effect of [ 111 In-DTPA 0 ]octreotide could be blocked by coinjection with a sst-saturating dose of unlabeled octreotide (100). As indicated above, it should be mentioned that 111 In is not a ␤-emitting radioisotope, but emits ␥-rays, internal conversion, and Auger electrons. Internal conversion and Auger electrons have a medium-to short-range tissue penetration (200 -500 m and 0.02-10 m, respectively), and it is suggested that these radiochemical properties of 111 90 Y is particularly effective in large tumors and 177 Lu seems most effective in small tumors (102) . Preliminary results in a rat model with tumors of more than one size indeed showed longer survival rates with the combined treatment, compared with treatment with the 90 Y-or 177 Lu-labeled SS-analogs alone (103) .
It is well known that tumor cells display various degrees of sensitivity to radiation. Adenovirus-based transfer of wild-type (wt) p53 tumor suppressor gene sensitizes ovarian tumor cells to radiation-induced apoptosis (104) . In addition, overexpression of the tumor suppressor gene Bax can sensitize tumor cells to radiation, as well as to chemotherapyinduced apoptosis (105, 106) . Of particular importance in this respect are recent studies demonstrating that octreotide induces wt p53 and Bax in MCF-7 human breast cancer cells (107) . SS-mediated induction of wt p53 and apoptosis is selectively induced via sst 3 (108) , in contrast to p53-independent, retinoblastoma protein-mediated signaling of cell cycle arrest (109, 110) . The majority of human sst-positive tumors express sst 3 (Section I). It cannot be excluded, therefore, that the therapeutic potential of internalized radionuclide may be limited by the lack of expression of a functional p53 or sst 3 . On the basis of their observations, Sharma and Srikant (107) suggested that ␣-or ␤-emitting octreotidetagged radionuclides should elicit maximal cytotoxic response due not only to radiation-induced damage after internalization, but also to the triggering of apoptosis via the induction of wt p53 and Bax by receptor-mediated signaling. Moreover, on the basis of these data, it is predicted that treatment with SS-analogs alone or in combination with radiation and/or chemotherapy will be most effective in treating wt p53-and sst-expressing tumors not only of the breast but also of other organs (107) . Taking the preclinical studies together, it can be concluded that radiotherapy using radiolabeled SS-analogs is effective in experimental sst-positive tumor models and that ssttargeted radionuclide therapy may be a feasible approach to treat patients with advanced, metastatic sst-positive neuroendocrine tumors.
Clinical evidence.
In 1989, the technique of sst scintigraphy to visualize sst-positive tumors in man was developed using the radiolabeled SS-analog [ 123 I-Tyr 3 ]octreotide (12) . Because the use of this radiopharmaceutical had a number of drawbacks (i.e., expensive, lack of availability, short physical halflife, and predominant hepatic clearance resulting in accumulation of radioactivity in liver, gall bladder, bile ducts, and gastrointestinal tract; Ref. 2), novel SS-analogs were developed to circumvent these disadvantages. As described above, the most widely used SS-analog for sst scintigraphy is a DTPA-coupled octreotide. The radioisotope 111 In binds with very high affinity to the DTPA molecule, and [ 111 In-DTPA 0 ]octreotide has proved to be a highly suitable radiopharmaceutical for the detection of sst-positive tumors by ␥-camera scintigraphy (13 2 with renal protection), a phase II study in 39 patients with progressive neuroendocrine, gastropancreatic, and bronchial tumors was performed (120) . The results showed an overall objective response rate of 23% (World Health Organization criteria: complete remission in 5%, partial remission in 18%, stable disease in 69%, progressive disease in 8%). In the patients with endocrine pancreatic tumors, objective response rate was 38% (13 patients). The overall clinical benefit in this study was 63%. Side effects were grade III or IV lymphocytopenia (23%), grade III anemia (3%), and grade II renal insufficiency (3% octreotide, and a 6-to 7-fold increase in affinity for their yttrium-loaded counterparts (91) . Preliminary promising results using this radiopharmaceutical have been reported (102, 103) .
C. SS receptor-targeted chemotherapy: preclinical evidence
The wide spectrum of adverse reactions when treating patients with advanced, metastatic tumors with chemotherapeutic agents are caused by the severe toxicity of these agents to normal cells. Like peptide receptor-targeted radiotherapy, targeted chemotherapy to deliver the chemotherapeutic compounds selectively to tumor cells might be a promising approach as well. Schally and Nagy (123) pioneered this concept with the development of cytotoxic analogs of LHRH, cytotoxic bombesin analogs, and cytotoxic SS-analogs, to treat LHRH receptor-, bombesin receptor-, and sst-positive tumors, respectively. This group of investigators provided preclinical evidence for the effectiveness of cytotoxic LHRH analogs in experimental models of human ovarian, mammary, or prostatic cancer (123) , as well as for the effectiveness of cytotoxic bombesin analogs in the treatment of experimental models of bombesin receptor-positive small cell lung carcinoma, colorectal, gastric, pancreatic, mammary, and prostatic cancers (123). Schally and co-work- (91) . In preclinical studies, it was demonstrated that both the AN-51 and AN-238 compounds inhibited tumor growth in experimental tumor models. In nude mice transplanted with the human Mia PaCa-2 pancreatic tumor, AN-51 significantly inhibited tumor growth, whereas the chemotherapeutic compound alone, methotrexate, or RC-121 alone had no significant inhibitory effect (124) , and with methotrexate alone displaying a much higher toxicity compared with AN-51. Thereafter, this group tested the cytotoxic properties of the AN-238 compound, which displayed a very high toxicity in sst-positive cells in vitro. Potent tumor growth inhibitory properties of AN-238 were observed in many experimental mouse and rat models of human breast cancer, prostate cancer, ovarian cancer, small cell lung cancer, pancreatic cancer, renal cell cancer, as well as glioblastoma (126 -133) . Again, a much higher toxicity and lower or absent effectiveness on tumor growth was observed in animals treated with the cytotoxic radical alone. In these animal studies, the major side effect of treatment with cytotoxic SS-analogs was a transient fall in white blood cell counts. In conclusion, sst-targeted chemotherapy is effective in preclinical tumor models and seems a highly promising approach as well to treat sst-positive tumors. The sst-targeted chemotherapy may result in a chemotherapeutic approach using lower dosages of the chemotherapeutic compound and thus lower toxicity. Until now, however, no clinical trials have been reported using targeted LHRH, bombesin, or SSanalogs. In addition, evidence will have to be provided that cytotoxic SS-analogs can also be internalized by sst-positive tumor cells. As for the concept of sst-targeted radiotherapy, the efficacy of sst-targeted chemotherapy will be determined by the amount of uptake of the cytotoxic radicals by the tumors. Moreover, the effect of cytotoxic SS-analog treatment on the function of normal sst-expressing cells is to be determined.
III. Tachyphylaxis and Resistance to SS
A. Introduction
Concomitant with the widespread distribution of sst throughout central and peripheral tissues, the acute administration of SS or its analogs induces a large number of mainly inhibitory effects (8, 9) . Nevertheless, these initially potent responses diminish with continued exposure (9, 11) . The different mechanisms that are potentially involved in this adaptation or tachyphylaxis to continuous exposure to SS or SS-analogs may be associated with processes such as receptor phosphorylation, G protein uncoupling, receptor internalization, and degradation. This has been reviewed extensively (8, 9) . Different from these physiological responses to continued SS exposure is the response of neuroendocrine tumor cells. Patients with certain types of sst-positive tumors (e.g., GH-secreting pituitary adenomas, islet cell tumors, and carcinoids) can be treated for many months to years with the current clinically available SS-analogs. The long-term control of hormonal hypersecretion and/or tumor growth by treatment with SS-analogs may vary considerably, however, among patients. Section III focuses particularly on tachyphylaxis and resistance to treatment with the different available formulations of SS-analogs, as well as the potential mechanisms involved herein. Although the direct fundamental evidence for the clinical observations of tachyphylaxis is relatively weak, several potential mechanisms determining cellular responsiveness to SS are discussed.
B. Tachyphylaxis of pathological hormone secretion
Pituitary adenomas.
Whereas normal hormone secretion shows tachyphylaxis after continuous receptor activation within hours to days (9), pathological hormone secretion by sst-positive tumor cells can be inhibited during significantly prolonged periods. In about half of the patients with GHsecreting pituitary adenomas, serum GH and IGF-I levels are normalized by octreotide treatment (134) . Escape from SSanalog therapy has not been observed in this type of patient, even after many years of continuous treatment (135) . Figure  2A shows a typical example of the persistent suppression of serum IGF-I levels in an acromegalic patient during a period of 8 yr of treatment with three times daily injections of 50 -100 g octreotide. The persistently lowered IGF-I levels seem not to be caused by radiotherapeutic effects because drug withdrawal after 5 yr of treatment resulted in an instant rise in IGF-I levels and immediate recurrence of signs and symptoms. Moreover, although no desensitization to continuous sc treatment with octreotide is observed, acromegalic patients treated with long-acting formulations of SS-analogs, i.e., long-acting repeatable octreotide administration (Refs. 135a-135c) or slow-release lanreotide (136) did not show any signs of tachyphylaxis to treatment periods up to 3 yr as well. To our knowledge, only one rare case of acromegaly showing desensitization to octreotide has been described so far (137) . Partial tachyphylaxis to SS-analogs was reported in a patient with acromegaly. In this patient, previously treated with 90 Y implant, external radiotherapy, and three daily sc injections with octreotide, GH levels progressively rose after switching to lanreotide and depot octreotide (Sandostatin LAR, Novartis Pharmaceuticals Corp., Basel, Switzerland). Interestingly, there were no signs of tumor growth or alterations in sst status as determined by [ 111 In-DTPA 0 ]octreotide scintigraphy (138) . Octreotide withdrawal for 24 h in this patient resulted in a 64% increased sensitivity in terms of inhibition of GH levels by recommencing octreotide treatment, suggesting that changes in receptor function or on the receptor signal transduction cascade play a role, rather than changes in receptor expression (138) .
The majority of TSH-secreting and clinically nonfunction-ing pituitary adenomas also express sst (139, 140) . Octreotide treatment of patients with TSH-secreting pituitary adenomas results in a lowering of TSH levels and normalization of T 4 levels in 73% of the patients. In contrast to patients with GH-secreting pituitary adenomas, in this series of 52 patients an escape from therapy was observed in 5 patients (10%). This loss of sensitivity to the inhibitory effect of octreotide on TSH levels was observed in two patients receiving short-term therapy and in three patients receiving long-term therapy (139) . Overall, Beck-Peccoz et al. (141) reported tachyphylaxis in 22% of the patients with a response to increasing octreotide doses, whereas subsequent escape from the inhibitory effects was observed in 10% of the cases. The role of SS-analogs in the treatment of patients with clinically nonfunctioning pituitary adenomas is less well established, whereas octreotide seems not of benefit in the treatment of patients with ACTHsecreting pituitary adenomas or prolactinomas (135) . This may be due to either the absence of sst on the tumor cells or the absence of expression of particular sst subtypes (135).
Islet cell tumors and carcinoids.
In striking contrast to the absence of the occurrence of tachyphylaxis of inhibition of hormone secretion by octreotide in patients with GH-secreting pituitary adenomas are the observations in patients with islet-cell tumors and carcinoids. In the majority of patients with metastatic carcinoids, VIPomas, gastrinomas, insulinomas, and glucagonomas, treatment with octreotide induces a rapid improvement of clinical symptomatology, such as diarrhea, dehydration, flushing attacks, hypokalemia, peptic ulceration, hypoglycemic attacks, and necrotic skin lesions (142) (143) (144) (145) . On the other hand, the majority of the patients show desensitization of the inhibition of the secretion of tumor-related hormones by octreotide within weeks to months. This effect may be initially reversed by increasing the dosage of octreotide, but eventually the drug becomes ineffective in all patients (11) . In a series of 57 patients with the carcinoid syndrome, 23 patients escaped from octreotide therapy after periods ranging from 1 wk to 12.5 months (median, 4 months), whereas the other responding patients could be controlled for periods extending to 2.5 yr. The estimated mean duration of response to octreotide therapy in the whole group of responding patients was approximately 1 yr (146) . Figure 2B shows a typical example of tachyphylaxis of the inhibitory effect of octreotide (100 g three times per day) on urinary 5-HIAA levels in a patient with a metastatic carcinoid tumor. An escape from octreotide treatment was seen after 3 months of therapy. Increasing the dose of
FIG. 2. Absence of tachyphylaxis to octreotide therapy in a patient with a GH-secreting pituitary adenoma (A) and desensitization in a patient with metastatic carcinoid tumor (B). A, Effect of octreotide therapy on serum IGF-I level in a patient with a GH-secreting pituitary adenoma.
A 77-yr-old man transsphenoidally operated (TSS) for a GH-secreting macroadenoma that had resulted in active acromegaly. Two months after incomplete surgery of the tumor, external radiotherapy (RT) was applied. Successively, octreotide therapy was started 6 months after surgery at a dose of 100 g three times daily. This therapy had resulted in a prolonged suppression of serum IGF-I levels (N Ͻ 43 nmol/liter) and disappearance of signs and symptoms of active acromegaly. Octreotide therapy has been continued for more than 8 yr. The dose could be reduced to 50 g three times daily. Discontinuation of therapy resulted in an increase of serum IGF-I levels and immediate recurrence of signs and symptoms of active acromegaly. Dotted line shows the upper normal limit of serum IGF-I levels. B, Effect of octreotide therapy on urinary 5-HIAA levels in a patient with a metastatic carcinoid tumor. A 66-yr-old man, operated for a metastatic carcinoid tumor of the small intestine with abdominal lymph node metastases, hepatic metastases, and the malignant carcinoid syndrome. Urinary 5-HIAA levels were greatly elevated (N Ͻ 40 mol/24 h). Therapy with octreotide was started at a dose of 100 g three times daily. This therapy initially resulted in a reduction of attacks of flushing and improvement of diarrhea, which was accompanied by more than 50% reduction (but not normalization) of urinary 5-HIAA levels. However, after 4 -6 months of therapy, the patient developed resistance to therapy: the flushing attacks, frequency of diarrhea, and urinary 5-HIAA levels gradually increased despite increasing the dose to 500 g three times daily. In addition, a slight increase of tumor mass was observed. The dotted line represents the upper normal limit of urinary 5-HIAA levels.
Hofland and Lamberts • SS Receptor Internalization Endocrine Reviews, February 2003, 24(1):28 -47 37 octreotide (to 500 g three times per day) was not beneficial in this particular patient. The potential mechanisms responsible for this desensitization, as well as for the considerable variability in the duration of the responses to octreotide therapy, are not known at present. The relatively long timeframe of this escape suggests mechanisms other than G protein uncoupling or internalization are involved. It has been suggested that this loss of sensitivity of endocrine cancers to octreotide is possibly associated with the outgrowth of clones of tumor cells that lack sst rather than with a transient downregulation of these receptors (147) . Moreover, it is not known why pituitary GH-secreting pituitary adenomas do not show tachyphylaxis to octreotide or lanreotide treatment, whereas the majority of patients with metastatic carcinoids, VIPomas, gastrinomas, insulinomas, and glucagonomas eventually desensitize. Possibly, SS-analog treatment of patients with GHsecreting pituitary adenomas induces an up-regulation of sst in the GH-secreting tumor cells, whereas other types of tumors display down-regulation of sst upon prolonged agonist exposure. As will be discussed in Section III.D.1, up-regulation and/or down-regulation of sst expression may be sst subtype dependent. As has been discussed in Section I, the majority of human sst-positive tumors express multiple sst subtypes, often with overlapping patterns. Therefore, potential tissue-specific desensitization and/or down-regulation of sst subtypes or, alternatively, tissue-specific upregulation of the octreotide-responsive sst subtypes 2, 3, and 5 induced by prolonged agonist treatment may account for continued responsiveness of GH-secreting pituitary adenomas to SS agonists.
C. Escape from antiproliferative effects
Apart from regulating neurotransmission and secretion, SS and its analogs may inhibit cell proliferation in normal and tumoral tissues as well. Evidence for inhibition of tumor cell proliferation by SS-analogs is based primarily on studies using experimental sst-positive tumor models (2, 3) . However, in a number of these studies, tumor growth is only delayed, because after a certain treatment period the tumors start to grow more rapidly, resulting in growth curves that parallel tumor growth in untreated control animals, indicating escape from SS-analog therapy (148 -150) . In the model of the transplantable prolactin (PRL)-secreting pituitary tumor (149), we observed during the first 2 wk of treatment with the SS-analog octreotide a significant reduction in tumor growth. After 2 wk of treatment, however, tumor growth rates in untreated and octreotide-treated animals were parallel and not significantly different. One of the mechanisms underlying this tachyphylaxis may be a downregulation of SS receptors on the tumor cells. In primary cultures of PRL-secreting 7315b cells, an incubation with octreotide for 1 wk inhibited both the growth and hormone secretion in a parallel and dose-dependent fashion. However, prolonged (5 wk) continuous exposure to octreotide (0.1 nm to 1 m) resulted in tachyphylaxis with respect to the inhibition of PRL secretion. In a stable cell line derived from this 7315b tumor, long-term exposure to octreotide induced a loss of sensitivity with respect to both PRL secretion and cell growth. This loss of sensitivity was accompanied by a complete down-regulation of SS binding sites on the tumor cells. In this 7315b sst-expressing tumor model, clonal selection of sst-negative cells was not the cause of desensitization, because withdrawal of treatment from desensitized cells resulted in a reappearance of sst and the sensitivity to octreotide (151) . A significant reduction in sst numbers induced by octreotide treatment has also been demonstrated in Syrian hamsters bearing transplanted insulinomas. Twice-daily injections with octreotide for 3 d resulted in a dose-dependent reduction in sst numbers on the insulinomas (2). On the other hand, the occurrence of tachyphylaxis to treatment with SSanalogs can be tumor cell type specific. In vivo studies by other groups showed an increase in SS-binding on experimental tumors treated with SS-analogs. Treatment of human MKN45 gastric carcinoma xenografts in nude mice for 5 wk with the SS-analog RC-160 significantly inhibited tumor growth without the occurrence of an escape. Daily sc injections with RC-160 even induced a significant up-regulation of sst in these tumors after 4 -5 wk, which in this particular tumor model may be beneficial in maintaining the inhibitory effects on tumor growth (152) . A comparable up-regulation of sst binding sites has been demonstrated in AR4-2J pancreatic tumor-bearing mice, in which continuous treatment (7 d) with a low dose of octreotide, administered via octreotidecontaining osmotic minipumps, induced an increase in the number of tumoral sst binding sites (153) . In contrast to this up-regulation of sst binding sites on pancreatic AR4-2J tumors by continuous in vivo treatment with low doses of octreotide, discontinuous (twice daily) sc injections of octreotide resulted in a down-regulation of sst expression (153) . After removal of octreotide in vitro, a total recovery of [ 125 ITyr 3 ]octreotide binding was observed within 24 h. This recovery was dependent on protein synthesis, making de novo receptor synthesis necessary for the recovery process (153) . RT-PCR analysis revealed that AR4-2J cells expressed sst 2 receptor mRNA only. In fact, these authors concluded that continuous treatment with a low dose of octreotide might improve the efficacy of long-term octreotide therapy. These data suggest that in a single tumor model the experimental conditions may determine whether sst 2 receptors are either down-regulated or up-regulated. In conclusion, the escape from the tumor growth-inhibitory effects of SS-analogs suggests that prolonged exposure to agonists may be due to sst down-regulation. Moreover, in some tumor models an upregulation of sst expression after agonist exposure has been observed, which might explain prolonged responsiveness to SS-analogs. These apparently opposite experimental results preclude making generalized conclusions with respect to the optimal SS-analog treatment modalities that might apply to patients with sst-positive neuroendocrine tumors. In addition, an escape from SS-analog treatment could, alternatively, involve an up-regulation of binding sites that do not recognize octreotide and/or an escape of tumor cells that do not express octreotide-responsive sst subtypes. In the majority of the above-mentioned studies, the precise mechanisms of changes in sst numbers were not studied in detail. Therefore, it remains to be established whether the changes in sst numbers at the cell surface are mediated via reduced sst gene transcription, decreased stability of sst mRNAs, via an increased intracellular breakdown of preexistent cellular SS receptors, or a combination of these events.
D. Mechanisms of tachyphylaxis and resistance
Homologous (down-)regulation of sst expression.
Although uncoupling from G proteins and internalization of SS receptors cannot be fully excluded as a potential cause for reduced sensitivity to long-term SS-analog treatment in patients with neuroendocrine tumors, other mechanisms are more likely to be involved. Down-regulation of cellular SS receptors may form a long-term cause of tachyphylaxis after continuous exposure of SS receptors to agonists. On the one hand, chronic exposure of cultured pituitary cells to relatively high concentrations of SS-14, SS-28, or SS-analogs reduces the number of sst on AtT20 and 7315b pituitary tumor cells (149, 151, 154, 155) . On the other hand, an up-regulation of sst expression has been observed in GH 4 C 1 or GH 3 rat pituitary tumor cells (156, 157) . This up-regulation of SS receptors in GH 4 C 1 or GH 3 was related to changes in sst gene expression, rather than changes in receptor affinity. In fact, in GH 3 cells, chronic exposure with SS induces an increase of sst 1 , sst 3 , sst 4 , and sst 5 mRNA expression after 6 -48 h of exposure, whereas sst 2 mRNA expression displayed a biphasic response, with an increase at 2 h, a decrease at 6 h, and finally normalization after 48 h (157) . Therefore, agonist-induced down-regulation and/or up-regulation of sst expression is time dependent and cell type specific. In cells that do not express sst subtypes endogenously, but were transfected with the different sst subtype genes to overexpress the different sst subtypes, agonist exposure has differential effects, depending on the sst subtype investigated. Short-term (1 h) agonist exposure decreases SS-binding in CHO cells expressing the sst 2A receptor (158, 159) , whereas prolonged exposure (22 h) to the peptide induces an increased binding (54). SS binding in cells expressing sst 3 and sst 5 receptors was not affected by SS pretreatment, whereas sst 4 and sst 1 receptors were up-regulated (54). Whether these sst subtype-specific responses to agonist exposure also occur in human sst-positive tumors, which express multiple sst subtypes, remains to be established. To our knowledge, no such data are available at present, except for clinical data on responsiveness and the induction of tachyphylaxis to SS-analog therapy (see Section III.B.2). Apart from agonist-induced changes in cell surface sst number, tachyphylaxis of responsiveness after chronic agonist exposure and/or resistance to SS-analog treatment may be induced by several other potential mechanisms as well. Such mechanisms include heterologous regulation of SS cell surface numbers, heterogeneous expression of SS receptors in human tumors, or sst gene mutations, and they are discussed in the following paragraphs. (160), probably via the inhibition of de novo protein synthesis. Moreover, sst subtype expression in GH 4 C 1 cells is differentially regulated by glucocorticoids. Short-term incubation for 2 h with dexamethasone increases sst 1 and sst 2 mRNA levels, whereas sst 3 mRNA levels were unchanged. On the other hand, prolonged exposure (2 d) with dexamethasone induced a reduction in sst 1 and sst 2 mRNA levels and a dramatic up-regulation of sst 3 mRNA levels. Nuclear run-on assays showed that the changes in sst 1 and sst 2 mRNA levels were associated with changes in sst gene transcription rate (161) . Indirect clinical evidence for the in vivo down-regulation of tumoral SS receptors by glucocorticoids was obtained from the observation that in five patients with untreated Cushings' disease, octreotide did not inhibit basal or CRH-stimulated ACTH levels and did not influence cortisol levels. In vitro, however, octreotide inhibited CRH-stimulated ACTH secretion by human corticotroph adenoma cultures, whereas this inhibitory effect was abolished by hydrocortisone pretreatment (162) . Estrogens have been shown to stimulate sst expression in pituitary (tumor) cells (163) (164) (165) in vitro and in vivo. Chronic estrogen treatment up-regulates sst 2 receptor mRNA expression in the anterior pituitary gland in vivo (166). Considerably less information is available regarding the heterologous regulation of sst expression in nonpituitary-derived cell systems. In breast cancer cell lines, estrogen stimulates steady state mRNA levels (167). A 5.3-kilobase pairs (kb) 5Ј-flanking region of the hsst 2 gene, lacking TATA and CCAAT boxes, is the active promotor in estrogen receptor-positive breast cancer cell lines (168). In agreement with these observations, Kimura et al. (169) recently demonstrated that estrogen regulated promotor activity of a 5-kb 5Ј-untranslated region of the rat sst 2 gene, lacking TATA and CCAAT boxes (169). In concordance with the findings in pituitary-derived cells, dexamethasone may cause down-regulation of sst numbers without changing receptor affinity in AR42J rat pancreatic acinar carcinoma cells (170). Thyroid hormones may regulate sst expression as well. In TtT-97 tumors, which represent an in vivo murine thyrotropic model not expressing any sst subtype mRNA or protein, thyroid hormone treatment induces specific up-regulation of sst 1 and sst 5 mRNAs and high affinity sst binding sites in the tumors (171). Taken together, these data demonstrate that sst subtype expression can be influenced by different steroids and hormones in a timespecific and receptor subtype-specific manner. It is not established, however, whether treatment of patients with, for example, glucocorticoids or antiestrogens may influence sst expression and thus responsiveness to SS in vivo as well. Apart from a regulatory effect of glucocorticoids and estrogens on sst expression, it is also likely that such agents directly influence the responsiveness of tumor cells to SS agonists. Indeed, breast cancer cells have been shown to respond better to the cytotoxic effect of octreotide in the presence of the antiestrogen tamoxifen (172). . This differential binding between octreotide on the one hand and SS-14/SS-28 ligands on the other hand, in insulinomas and other subgroups of sst-positive tumors, suggests that resistance to octapeptide SS-analogs may be due to the absence of specific sst subtypes that bind these analogs with high affinity, but also indicates that novel sst subtype-selective analogs can be developed for the treatment of patients with tumors carrying sst of this particular subtype(s). Although certain human sst-positive tumors lack particular sst subtypes with high affinity for octapeptide SS-analogs (Table 1) , some tumors have been demonstrated to express a nonhomogenous distribution of SS receptors (23-25). A nonhomogenous distribution of sst has been found in a subset (3 of 10) of human GH-secreting pituitary adenomas (173), as well as in rare cases of carcinoid tumors (23). Moreover, in more than 50% of breast cancer specimens, sst expression displayed a nonhomogenous distribution, i.e., both sst-positive and sstnegative tumor regions within individual sst-positive tumors (174). One rare case of a human carcinoid tumor has been described in which sst 1 and sst 2 mRNA were clearly localized in different tumor regions (28). In such cases, resistance to SS-analog therapy, after an initial response, may be due to the outgrowth of sst (sst 2 )-negative tumor cell clones, which in fact may still express sst, albeit of the subtype to which the current generation of octapeptide SSanalogs do not bind.
b. SS receptor gene mutations.
To date, relatively few data are available with respect to sst-gene mutations leading to a loss of sst function. One study addressed this issue so far in COR-L103 small cell lung cancer cells (175). Sequence analysis of the sst 2 gene demonstrated a point mutation in codon 188 of TGG for tryptophan to TGA for a stop codon causing a loss of 182 C-terminal amino acid residues in sst 2 , resulting in the absence of sst 2 expression in the plasma membrane of COR-L103 cells. The nucleotide sequences of the sst 3 and sst 4 genes, which were also expressed in these cells, were normal. In a series of 19 human GH-secreting pituitary adenomas with variable sensitivity to SS-analog treatment in vivo, the sst 2 and sst 5 genes were found to possess intact coding sequences (176). Moreover, no mutations affecting the sst 2 protein were detected in a series of 15 GH-secreting pituitary adenomas (177). These data suggest that mutations in these sst subtypes do not form the basis for resistance of tumoral GH secretion to SS-analogs. Ballare et al. (178) recently described a germ line mutation (Arg240Trp) in the sst 5 gene in an acromegalic patient resistant to SS-analog treatment. This mutation results in decreased sensitivity to the inhibitory effect of SS on adenylate cyclase activity, whereas cells expressing the mutant sst 5 displayed increased proliferation and increased MAPK activity, compared with wt cells. These data suggest that this mutation in sst 5 abrogated the antiproliferative action by SS and activated mitogenic pathways. Nevertheless, such mutations appear to be very rare. Finally, in none of a series of 43 neuroblastoma tumors were mutations in the sst 2 gene detected by PCR-based single-stranded conformation polymorphism/heteroduplex analysis (179). Mutations in other sst subtypes that may cause this resistance cannot be excluded, however. Moreover, other causes such as sst density and/or the above-discussed mechanisms of resistance (summarized in Table 4 ) may play a role as well.
c. Miscellaneous potential causes of resistance to SS-analogs.
Antibodies to octreotide that develop in patients treated with this analog (138, 180 -182) seem not to be an important cause of escape from therapy with SS-analogs, because continued efficacy of octreotide treatment has been documented in two acromegalic patients who had antibodies to octreotide (181). G protein mutations, particularly mutations in G s ␣, have been shown to be associated with overproduction of hormones by pituitary-derived hormones, as well as with pituitary hyperplasia (183) . In a subgroup of patients with GHsecreting pituitary adenomas, high basal adenylyl cyclase activity and poor responsiveness to stimulatory agents such as GH-releasing hormone suggested constitutive activation of the adenylyl cyclase cascade in the tumor cells. A considerable number of these tumors indeed contained an activating mutation in G s ␣ (183), which correlates with a higher sensitivity to SS agonists. An increase in sst 2 mRNA does not seem to account for this increased sensitivity (184) . However, mutations in inhibitory G proteins are rare, and mutations in G i 2␣, to which sst 2 is capable of associating (185), have only been described in small numbers of adrenal cortical tumors (27%) and ovarian tumors (30%; Ref. 186 ). It appears therefore, that resistance to SS-analog therapy due to a mutation in inhibitory G proteins coupled to sst is not very likely to occur.
E. New developments
As described in Section III.D.3, one of the causes for resistance to therapy with the current generation of octapeptide SS-analogs may be the absence or low expression of sst 2 receptors by the tumor cells. The question then arises: What might be the role of other sst subtypes as a target for therapy with novel SS-analogs? Functional evidence for the existence of sst subtypes comes from studies using human fetal pituitary cell cultures in which SS regulates GH and TSH secretion by both sst 2 and sst 5 , and PRL secretion mainly by sst 2 (74) . In recent years, many new sst selective analogs have been synthesized. Using primary cultures of human GHsecreting pituitary adenomas, Melmed and co-workers (75) demonstrated that combinations of sst 2 -and sst 5 -selective (Table 1) has been shown to have a much higher efficacy in lowering normal plasma IGF-I levels in rats, compared with the effects of the sst 2 -selective analog octreotide (188) . Long-term (weeks to months) continuous, as well as discontinuous, treatment with octreotide in rats is known to result in a loss of the inhibitory effect of the drug on circulating GH and IGF-I levels (148, 149, 189) . The potent inhibitory effect of SOM230 on IGF-I levels, showing no signs of loss of its inhibitory effect during a period of 126 d of continuous infusion, could be explained by a 40-fold increase in the affinity for sst 5 receptors, as compared with octreotide in combination with the key role that sst 5 plays in controlling GH release (75, 187) . SOM230 has a very long terminal elimination half-life of 23 h in rats, compared with octreotide (2 h), and no obvious adverse side effects, including changes in glucose levels, over the 126-d period of treatment, and it is currently under evaluation in phase I trials (188) . Moreover, sst subtypes may form homo-or heterodimers (56, 58) or may heterodimerize with other G protein-coupled receptors such as the dopamine D2 receptor (60) or the opioid receptor MOR-1 (59), resulting in a novel receptor state with properties distinct from the individual receptors in terms of enhanced internalization, reduced agonist-induced desensitization, and functional activity. These new fundamental insights into receptor function will help us to explain the observed differences in the development of tachyphylaxis not only between patients with different tumor types, but also among patients with the same type of neuroendocrine tumor but with different sst subtype expression patterns. It is a challenge to evaluate whether these new bispecific or more universal SS-analogs are indeed effective in tumors resistant to the current clinically available compounds as octreotide and lanreotide, as well as to investigate whether such new compounds can prevent neuroendocrine tumors from tachyphylaxis to treatment. Apart from new analogs with a broader sst binding profile, a hybrid SS-dopamine molecule has also been recently synthesized. This molecule, BIM-23A387, retained high affinity binding to both sst 2 and D2 receptors and had a tremendous enhanced potency on GH and PRL release by primary cultures of human pituitary adenoma cells, compared with sst 2 -and D2-specific analogs, alone or in combination (190) . This significant enhanced potency, however, could not be explained on the basis of the binding affinity of the compounds for sst 2 and D2 receptors (190) . The mechanism by which this molecule exerts its potent action is unknown but strengthens the observations that processes like heterodimerization of receptors indeed have functional implications.
F. Conclusions
The induction of tachyphylaxis of responsiveness to SSagonists has been demonstrated in a variety of sst-positive cell systems. The time-frame of the occurrence of tachyphylaxis in vivo on normal hormone secretion is relatively rapid (hours to days), whereas escape from therapy with SSanalogs in patients with sst-positive tumors or in experimental models of sst-positive tumors generally occurs after prolonged exposure to SS agonists (weeks to years). This relative late induction of tachyphylaxis of responsiveness suggests that sst down-regulation, rather than rapid processes like G protein uncoupling and/or receptor internalization are involved. Moreover, escape from SS-analog therapy could involve the outgrowth of tumor cell clones lacking the expression of sst subtypes to which the currently clinically used octapeptide analogs bind with high affinity. The development of novel sst subtype-selective and nonselective analogs, as well as chimeric compounds, could be of interest as potential new treatment modalities for resistant tumors. The only group of tumors that show no signs of desensitization to treatment with SS-analogs are GH-secreting pituitary adenomas. In SS-analog-sensitive patients with GH-secreting pituitary adenomas, circulating GH and IGF-I concentrations can be effectively suppressed, even during many years of treatment with these compounds. The underlying mechanisms for this difference in developing tachyphylaxis to SS-analog treatment between GH-secreting pituitary adenomas on the one hand, and other types of neuroendocrine tumors on the other hand, have not yet been elucidated but could involve the differential expression of sst subtypes, a tissue-specific desensitization, and/or downregulation of sst subtypes, or alternatively, tissue-specific upregulation of SS-analog responsive sst subtypes by prolonged agonist treatment resulting in continued responsiveness.
In conclusion, clinical observations clearly demonstrate tachyphylaxis and/or resistance to SS-analog treatment in patients with neuroendocrine tumors, but the direct fundamental evidence explaining the mechanisms involved is currently weak.
IV. Summary
During the past decade, novel insights into the physiological and pathophysiological role of SS and its receptors have been developed. Although in the mid-1980s it was debated whether or not SS was internalized by sst-expressing cells, recent studies have now clearly demonstrated that SS and SS-analogs are efficiently internalized via a rapid process of agonist-induced receptor-mediated endocytosis. Moreover, in 1989 the technique of sst scintigraphy to visualize sst-positive tumors in humans was developed, and the concept of the radiotherapeutic use of radioisotope-coupled SS- tumor size in patients with advanced sst-positive neuroendocrine tumors. Finally, the concept of targeted chemotherapy to deliver chemotherapeutic compounds selectively to sst-positive tumor cells, thereby reducing their toxicity, has now been validated using newly developed cytotoxic SS-analogs in experimental mouse and rat models of human pancreatic, breast, prostate, ovarian, and small cell lung cancer.
The presence of sst 2 receptors in tumors is a prerequisite for sensitivity of inhibition of tumor-related hormonal hypersecretion to treatment with octapeptide SS-analogs. The successful clinical application of SS-analogs such as octreotide and lanreotide in the treatment of hormonal hypersecretion in patients with GH-secreting pituitary adenomas and islet cell or carcinoid tumors is caused by the predominant expression of sst 2 receptors in these tumors. On the other hand, novel sst subtype-selective analogs, as well as bispecific and more universal agonists, have been synthesized now and were demonstrated to be effective in the in vitro inhibition of hormone secretion of sst-positive tumors that do not express sst 2 receptors. Patients with sst-positive tumors also show considerable variability in their responsiveness to treatment with SS-analogs. Patients with GHsecreting pituitary adenomas do not show desensitization to treatment with SS-analogs, whereas patients with islet cell or carcinoid tumors often demonstrate tachyphylaxis to treatment. The occurrence of tachyphylaxis upon treatment with SS-analogs is highly variable. Some patients escape very rapidly, whereas others show tachyphylaxis only after several years of treatment. Nevertheless, despite the increasing fundamental knowledge on the role of individual sst subtypes in agonist-induced internalization and/or desensitization of sst subtypes, as well as in agonist-induced, sst subtype-specific regulation of sst expression and receptor homo-and heterodimerization, the direct fundamental evidence for the observed differences between patients with neuroendocrine tumors in the development of tachyphylaxis to SS-analogs is currently weak and requires further studies. 
